According to the median SFXN3 expression, 25 newly diagnosed non-M3 AML patients were divided into high SFXN3 expression (SFXN3-H) group (n = 13) and low SFXN3 expression (SFXN3-L) groups (n = 12). Here, SFXN3 is linked to acute myeloid leukemia.